

Sistema de Apoyo a la Toma de Decisiones Mejorado por Gemelos Digitales en Diabetes Tipo 1 con Terapia MDI

Carlos Builes, Laura Lema, Hernan Alvarez, and

José García-Tirado


Department of Diabetes, Endocrinology, Nutritional
Science, and Metabolism (UDEM)



jose.garcia@unibe.ch

Prof. Jose Omar Silverman- Retana

Internacionalización de la estrategia de investigación del SDCA





Background

1

“All models are wrong, but some are useful.” *George P. E. Box*

People with Type 1 Diabetes (PwT1D) need a lifelong insulin replacement (MDI or CSII) to keep glucose levels in the desired range.



Diabetes Control and
Complication Trial (DCCT)

Intensive Insulin Therapy (IIT)




HbA1c



Hypoglycemia



Current insulin preparations



Background Current Landscape

YPSOMED
SELF CARE SOLUTIONS



CamAPS/FX

diabeloop



DBLG1

TIDEPOOL



APP

Beta Bionics



iLet (insulin-only)

Medtronic



670G, 770G, 780G

TANDEM
DIABETES CARE



Control-IQ

Insulet



Omnipod 5


Background

Current Landscape

While developed countries are reaching high levels of technology adoption, countries in development are lagging behind:


(US and Europe)

50-70%



LATAM, Asia, Africa

10-20%



Mathematical Models and the Medical Digital Twin Technology


2

What is a Model?

“A model is an imitation of reality; a representation of a system, entity, phenomenon, or process” [a]


Subclasses, according to Batzel et al. [b]:

a. Conceptual models



Harvey's circulation model (1628) [c]

b. Physical models



c. Mathematical models

$$\Sigma: \begin{cases} \dot{x} = f(x, u, d, \theta, t) \\ y = g(x, u) \end{cases}$$


[a] Kaizer JS, Heller AK, Oberkampf WL. 2015. Scientific computer simulation review. *Reliab. Eng. Syst. Saf.* 138:210–18

[b] Batzel J, Bachar M, Karemaker JM, Kappel F. 2012. Merging mathematical and physiological knowledge: dimensions and challenges.


[c] Schultz SG. 2002. William Harvey and the circulation of the blood: the birth of a scientific revolution and modern physiology. *News Physiol. Sci.* 17:175–80

What is a Model?

According to where the equations come from:




White-Box Models




mechanistic – phenomenological – first principles

Their basic derivation comes from system phenomena or mechanisms such as mass, energy, and momentum transfer.



$$\left\{ \begin{array}{c} \text{net change} \\ \text{of quantity in time} \end{array} \right\} = \left\{ \begin{array}{c} \text{flow in} \\ \text{through boundary} \end{array} \right\} - \left\{ \begin{array}{c} \text{flow out} \\ \text{through boundary} \end{array} \right\} \\ + \left\{ \begin{array}{c} \text{net} \\ \text{generation} \end{array} \right\} - \left\{ \begin{array}{c} \text{net} \\ \text{consumption} \end{array} \right\}.$$






empirical – input/output


Are the result of experiment and observation (equation fitting where the parameters have little or no physical meaning)

- Time series (lots of...)
- Neural networks
- Transfer functions
- Deep Learning
- Machine Learning
- Recommendation engines
- Predictive analytics
- NLP / Text mining
- Natural language generation
- Etc...



The Digital Twin

The concept of a virtual, digital equivalent to a physical product, or the Digital Twin (DT) was introduced by M. Grieves in 2003 at the University of Michigan (in a lecture).



In the following two decades, there has been a tremendous progress in

1. Amount, richness, and quality of the information.
2. Computational capacity.



Key enablers of
Precision Medicine

The Digital Twin (Medicine)

DTs can be defined as (physical and/or virtual) machines or computer-based models that are *simulating, emulating, mirroring, or “twinning”* the life of a physical entity, which may be an object, a process, a human, or a human-related feature [d].

As such, DT in Medicine does not need to be a virtual copy of the entire individual




[d] Barricelli, B. et al A Survey on DT: Definitions, Characteristics, Applications, and Design Implications.

Decision Support System (DSS) to Assist PwT1D with Meal Bolusing

3


Several times per day, in the mind of a PwT1D:



1. Decide what to eat
2. Monitor the BG level
3. Estimate the carb content
4. Inject insulin as a function of 2. (CF) and 3. (CR)



Some studies have shown systematic estimation errors ~ 20%



Carb counting as a decision-making process



Challenge

Glucose will
change with food

A Simulation


=

What if?

Goal

Keep glucose
within the range





1. Lema-Perez, L. et al., 2019. *Journal of theoretical biology*, 460, pp.88-100.
2. Builes-Montañó, C.E. et al., 2022. *Computers in Biology and Medicine*, 142, p.105232.
3. Lema-Perez, L., et al., 2023. *Plos one*, 18(5), p.e0285849.

Randomized parallel-arm clinical trial

- age 18 – 70 years old, with T1D >1yr
- User of CGM


4 weeks data collection (home)

- CGM, insulin, carb estimation

Home portion (four weeks)

At every meal:

- Scan the sensor
- Enter the BG into the app
- Estimate carbs
- Run



Baseline characteristics

	Control (N=14)	STUDIA (N=14)
Age	26.0 (23.0 - 42.5)	39.5 (32.3 - 54.8)
Sex		
Female	8 (57.1)	6 (42.9)
Male	6 (42.9)	8 (57.1)
Timen in range	59.9 (20.8)	63.4 (23.7)
Time counting carbohydrates		
Less than a year	1 (7.1%)	2 (14.3)
More than a year	13 (92.9%)	12 (85.7)
Education		
Secondary	5 (35.7%)	3 (21.4%)
Post-Secondary	9 (64.3%)	11 (78.6%)
Insulin pump users	2 (14.28%)	1 (7.14%)
Glycated hemoglobin	7.29 (1.00)	7.27 (0.873)
Coefficient of variation	36.4 (32.8, 40.2)	33.6 (28.4, 36.8)
DTSQ	28.5 (26.3, 29.8)	28.5 (23.3, 31.5)

Recruitment

Phase	# participants
Assessed	68
Withdrew (before)	32
Screen fail	8
Randomized	28
Dropped-off	0
Finished	28

Table 2. Primary and secondary outcomes*

Outcome	Control (N=14)	STUDIA (N=14)	Estimated Adjusted Difference (95%CI)	P Value
Change in TIR	-3.71±12	7.93±11.3	6.95 (3.51 to 10.39)	<0.001
Change in TBR level 1	1.93±2.89	-1.64±2.10	-1.10 (-2.20 to -0.20)	0.022
Change in TBR level 2	0.71±0.80	-0.28±0.56	-0.11 (-0.39 to 0.17)	0.422
Change in TAR level 1	1.43±13.3	-3.93±13.6	-3.21 (-7.67 to 1.25)	0.396
Change in TAR level 2	2.61±2.5	1.78±1.68	-1.01 (-3.03 to 1.0)	0.303
Change in CV	-1.09±3.4	0.0357±7.7	0.38 (-2.41 to 3.17)	0.787

*Metrics are computed using all data from the scans.

We assessed the prediction ability of the model within the control group (the ones who were not 'persuaded' by simulations)

$$RMSE_j = \sqrt{\frac{\sum_{i=1}^n (\{y_i\}_j - \{\hat{y}_i\}_j)^2}{n}}$$

y_i : i -th CGM measurement

\hat{y}_i : i -th element of the model prediction

14 participants (**Control Group**)


Total: 277 meals → ~ 20 meals per person per 30 days → ~ 22% of the expected use

We selected for the analysis 10 participants: >50% of the expected use


$\min(\text{RMSE}) = 1.24 \text{ mg/dL}$

$\max(\text{RMSE}) = 26.29 \text{ mg/dL}$


All the participants



RMSE's Per Participant




Best RMSE = 1.24 mg/dL



Participant 1

Worst RMSE: 26.29 mg/dL



Participant 3

- Simulation of meal scenarios appears as a promising tool for conscious decision-making
- Although most CTs using decision-support systems in T1D have shown marginal benefits, our approach reached a clinically significant increase in TIR in a suboptimally controlled population.
- Although simulation accuracy may seem not indispensable in this context, it has the potential to impact user trust
- We achieved an overall median RMSE of 10.5 mg/dL in 277 4-h predictions, which is on the lower side of what's typically observed from the literature 15-30 mg/dL (~2h predictions).
- Future work will include studies with rtCGM and a more established methodology for model calibration/validation

Carlos Builes, MD, PhD.

Laura Lema, PhD.

Hernan Alvarez, PhD.

Asociación Colombiana de Endocrinología (ACE)

The participants

